Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.

Keywords

Gefitinib, Medicine, Interstitial lung disease, Erlotinib, Radiology

References

• Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.Hiroko Suzuki, Kazutetsu Aoshiba, Naoko Yokohori — 2003
• Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii — 2008
• Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha.William D. Hardie, Daniel R. Prows, Alyssa Piljan-Gentle — 2002
• Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.Masahiko Ando, Isamu Okamoto, Nobuyuki Yamamoto — 2006
• Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-α.William D. Hardie, Daniel R. Prows, George D. Leikauf — 1999

Cited by

• Erlotinib-Associated Interstitial Lung Disease in Advanced Pancreatic Carcinoma: A Case Report and Literature ReviewMarianna Macerelli, Micol Mazzer, Luisa Foltran — 2015
• Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.Shih‐Chieh Chang, Shih‐Chieh Chang, Cheng‐Yu Chang — 2013
• Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.Tomoyuki Araya, Kazuo Kasahara, Yoshiki Demura — 2013
• Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.Ko-Fan Wang, Cheng‐Yu Chang, Shih‐Chieh Chang — 2013
• Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.Yosuke Togashi, Katsuhiro Masago, Shiro Fujita — 2011
• Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.Yosuke Togashi, Katsuhiro Masago, Tomohiro Handa — 2012
• Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.Shinji Nakamichi, Kaoru Kubota, Hidehito Horinouchi — 2013
• Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.Yosuke Togashi, Katsuhiro Masago, Yasuhiro Hamatani — 2012
• Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.Cristina Bugés, Enric Carcereny, Teresa Morán — 2015
• Recurrent Interstitial Lung Disease Induced By Various Therapies forNon-Small Cell Lung CancerYu Saida Satoshi Watanabe — 2014
• Functional analysis of mutant receptor tyrosine kinases involved in cancer pathogenesisRama Krishna Kancha — 2010
• ゲフィチニブによりradiation recall pneumonitisを発症したEGFR遺伝子変異陽性肺腺癌の1例Minoru Inomata, Toshimichi Miya, Yutaka Kokubo — 2010
• Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicityHiroto Ueda, Hidetoshi Hayashi, Keita Kudo — 2016
• Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung CancerChristopher Jakubowski, Andrew J. Plodkowski, Jason C. Chang — 2016
• The ATS/ERS/JRS/ALAT Statement “IPF by HRCT” could Predict Acute Exacerbation of Interstitial Lung Disease in Non-small Cell Lung CancerNobuhiro Asai, Eisuke Katsuda, Rie Hamanaka — 2017
• Successful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lungTomoyuki Otsuka, Aya Tanaka, Hiroaki Azukizawa — 2016
• Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung diseaseKosuke Kashiwabara, Hiroshi Semba, Shinji Fujii — 2017
• Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung DiseaseTatsunori Kiriu, Daisuke Tamura, Motoko Tachihara — 2017
• Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinomaShingo Satoh, Takayuki Shiroyama, Motohiro Tamiya — 2017
• Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung DiseaseKosuke Kashiwabara, Hiroshi Semba, Shinji Fujii — 2018

Related papers

• Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinibDavid F. Heigener, Martin Reck — 2011
• An illustration of survival analysis: A study of intensive care unit patientsR. Estarelles, J. Pascori — 1991
• Role of Epidermal Growth Factor Receptor Mutational Testing in Personalising the Treatment of Non-small-cell Lung CancerPhilip J Ginsburg — 2010
• Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitorsMasahiro Tsuboi, Thierry Le Chevalier — 2006
• Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutationKenichi Suda, Kenji Tomizawa, Tetsuya Mitsudomi — 2010
• Use of novel second-line targeted therapies in non-small cell lung cancer.Erminia Massarelli, Roy S. Herbst — 2006
• Is the Target therapy have a role in the treatment of Metastatic lung cancer in patients who is not fit for chemotherapy? Case ReportAyman Rasmy, Mohamed Mashiaki, Amal Ameen — 2018
• An active treatment of lung adenocarcinoma cancer with brain metastases: icotinibYing Zhang, Jun Li, Huaping Tang — 2015
• Epidermal Growth Factor Receptor Mutations Are Associated with Docetaxel Sensitivity in Lung CancerTatsuya Yoshimasu, Shoji Oura, Fuminori Ohta — 2011
• EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” OsimertinibKeigo Kobayashi, Katsuhiko Naoki, Aoi Kuroda — 2017